| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Over the past 90 days, insiders at Seres Therapeutics, Inc. (MCRB) have been net sellers, shedding 490 shares worth roughly $2K on balance.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 12.5K | $24.5K | - | |
| Other | 8.7K | $17.0K | - | |
| Other | 8.6K | $16.8K | - | |
| Other | 8.1K | $15.9K | - | |
| Other | 8.0K | $15.7K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 1, 2020 | Matthew R. Henn69 | See Remarks | Sale+OE | 91,812 | $27.04 | $2,482,308.70 | - | |
| Nov 22, 2019 | Marcus Chapman | See Remarks | Sale+OE | 3,400 | $3.91 | $13,296.72 | -28.3% | |
| Jun 18, 2019 | Noubar Afeyan74 | Director, 10% Owner | Buy | 8,888,888 | $2.25 | $19,999,998.00 | -200.0% | |
| Jan 28, 2019 | Eric D. Shaff69 | See Remarks | Sale+OE | 4,378 | $5.75 | $25,187.51 | -25.4% | |
| Jan 28, 2019 | Thomas DesRosier69 | Chief Legal Officer and EVP | Sale+OE | 5,471 | $5.75 | $31,477.95 | -25.4% | |
| Dec 17, 2018 | John G. Aunins | Chief Technology Officer & EVP | Sale+OE | 14,282 | $6.39 | $91,313.40 | -16.0% | |
| Nov 15, 2018 | John G. Aunins | See Remarks | Sell | 14,279 | $8.26 | $117,911.70 | -13.8% | |
| Oct 15, 2018 | John G. Aunins | See Remarks | Sell | 14,279 | $5.94 | $84,800.13 | -12.1% | |
| Sep 17, 2018 | John G. Aunins | See Remarks | Sell | 42,837 | $7.64 | $327,344.65 | -26.6% | |
| Sep 7, 2018 | Roger Pomerantz | President and CEO | Sell | 1,810 | $9.00 | $16,291.27 | -0.8% |